The short version
- Why people research itTanning and photoprotection via melanogenesis.
- What the evidence isNo trials for cosmetic tanning.
- What to watchA mole that changes size, border or color, or a new dark spot.
How Melanotan 1 works
Linear alpha-MSH analog ([Nle4,D-Phe7]-alpha-MSH) that drives melanin via MC1R — not receptor-selective: it also binds MC3R and MC4R (PMIDs 8761313, 9813305).
This compound is an approved medicine, and almost nothing written about it in this market says so. Afamelanotide is the active ingredient of SCENESSE, approved by the FDA in 2019 to “increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)” U.S.
The chemistry, and two substitutions carry all of it. The label describes afamelanotide as “a synthetic tridecapeptide and a structural analog of alpha-melanocyte stimulating hormone (α-MSH)” that is “a melanocortin receptor agonist and binds predominantly to MC1-R” U.S. Food and Drug Administration 2019.
- Injectable
- Nasal
On the goal map: Pigment, tone & photoprotection (Skin, hair & aesthetics)
Research on Melanotan 15 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Approved (Scenesse, EPP); human.
Human clinical evidence
Approved in Europe and the US as afamelanotide (Scenesse) for erythropoietic protoporphyria, on randomized trial data showing increased pain-free light exposure. That is a real approval for a real melanocortin analog.
No trials for cosmetic tanning.
No completed human trial
Correlative data
Used for tanning and photoprotection. Compared with Melanotan 2 the reported profile is markedly cleaner — little to no nausea, flushing or sexual effect — which is exactly what the selectivity predicts.
How the mechanism reads
A selective MC1R agonist — the melanocyte receptor — without meaningful MC3R/MC4R activity.
MechanisticThat single difference from Melanotan 2 explains the entire difference in experience: MT2 is unselective and hits the appetite and libido receptors too. The shared MC1R action means the mole and skin-check caution applies to both, since stimulating melanocytes is the mechanism in each case.
Mechanistic
Sources
- U.S. Food and Drug Administration. SCENESSE (afamelanotide) implant, for subcutaneous use - full prescribing information (NDA 210797).. FDA approved labeling, revision 2019
- Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for Erythropoietic Protoporphyria.. N Engl J Med 2015 · PMID 26132941
- Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.. Br J Dermatol 2015 · PMID 25494545
- Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ. Skin pigmentation and pharmacokinetics of melanotan-I in humans.. Biopharm Drug Dispos 1997 · PMID 9113347
- Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.. Photochem Photobiol 2000 · PMID 11045725
- Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed sun tan jab.. BMJ 2009 · PMID 19174439
Melanotan 1 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Personal or family history of melanoma, or many atypical moles: MC1R stimulation changes pigment cells you need to watch.
- Pregnancy or breastfeeding: afamelanotide has little data there.
- Uncontrolled liver disease: the approved implant label cautions on hepatic impairment.
- Under 18: no pigment-cell safety data for adolescents outside approved use.
What’s expected
- Gradual darkening of skin and freckles through MC1R-driven melanin, strongest on sun-exposed areas.
- Mild nausea or flushing, since melanocortin receptors also sit in the gut and vessels.
- Existing moles may look darker.
Watch for
- A mole that changes size, border or color, or a new dark spot.
- Skin darkening that is patchy, uneven or very fast.
- Fainting or lightheadedness when you stand.
Labs that tell you it’s working
- Comprehensive Metabolic Panel (CMP)
- Vitamin D (25-Hydroxy)
- Ferritin
- Complete Blood Count (CBC) w/ Differential
Afamelanotide is not MC1R-selective (it binds MC3R and MC4R too, PMID 9813305): the main harms are pigment and skin effects, and MC4R effects such as nausea, libido and blood-pressure change are possible. PMID 26132941 PMID 25494545
Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Melanotan 1 FAQ4 common questions
- Is Melanotan 1 approved for human use?
- Melanotan 1 is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Melanotan 1 researched for?
- Tanning and photoprotection via melanogenesis.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Vitamin D; Ferritin; Complete Blood Count: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Melanotan 1: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




